International Journal of Hypertension [14] K. M. Anderson, P. M. Odell, P. W. Wilson, and W. B. Kannel, “Cardiovascular disease risk proﬁles,” American Heart Journal, vol. 121, no. 1, part 2, pp. 293–298, 1991. [15] A. Peeters, J. Ting, M. Nelson, and J. J. McNeil, “Coronary heart disease risk prediction by general practitioners in Victoria,” Medical Journal of Australia, vol. 180, no. 5, p. 252, 2004. [16] S. J. Pocock, V. McCormack, F. Gueyﬃer, F. Boutitie, R. H. Fagard, and J. P. A. Boissel, “A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials,” British Medical Journal, vol. 323, no. 7304, pp. 75–81, 2001. [17] M. R. Nelson, P. Ryan, A. M. Tonkin et al., “Prediction of cardiovascular events in subjects in the second Australian national blood pressure study,” Hypertension, vol. 56, no. 1, pp. 44–48, 2010. [18] Z. Wang and W. E. Hoy, “Is the Framingham coronary heart disease absolute risk function applicable to aboriginal people?” Medical Journal of Australia, vol. 182, no. 2, pp. 66–69, 2005. [19] S. Yusuf, P. Sleight, J. Pogue et al., “Eﬀects of an angiotensin- converting-enzyme inhibitor, ramipril, on death from cardio- vascular causes, myocardial infarction, and stroke in high-risk patients,” The New England Journal of Medicine, vol. 342, no. 3, pp. 145–153, 2000. [20] E. B. J. Lonn, K. K. Teo, P. Pais, D. Xavier, and S. Yusuf, “The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions,” Circulation, vol. 122, no. 20, pp. 2087–2088, 2010. 3